John Isacson focuses on representing clients in the pharmaceutical, biotechnology, chemical and medical device industries in all patent-related matters. His clients include internationally recognized research and health care institutions, emerging ventures, investors, and large public corporations.
A registered patent attorney, John has particular experience in strategic counseling and patent portfolio management, infringement litigation, due diligence, inter partes and post-grant reviews, reexaminations, patent interferences, inventorship and ownership disputes, biosimilars, and Hatch-Waxman. He is regularly involved in litigation and U.S. Patent and Trademark Office proceedings. John also advises on related FDA matters for certain technologies.
In his pro bono practice, John counsels military veterans through his work with the National Veterans Legal Services Program, an organization that has helped veterans to obtain disability benefits.
Representative Matters
Represented a multinational biopharmaceutical company in intellectual property matters related to a multibillion-dollar acquisition.
Developed strategies and patent portfolios for recombinant poxviruses, which involved a patent interference, a district court action, and multiple ex parte appeals to the board.
Prevailed in an interference proceeding and obtained a precedential affirmance from the Federal Circuit for a biotechnology company’s patent.
Prevailed in an interference proceeding, which resulted in issuance of a patent for transgenic corn.
Prevailed in inter partes review proceedings to invalidate patent claims.
Successfully prosecuted an application for recombinant von Willebrand Factor, leading to a U.S. patent having pre-GATT term, issued in 2013.
Strategized and developed multigenerational worldwide patent portfolios for orthopedic implants for a leading teaching hospital.
Successfully prosecuted patent applications for biotechnology and pharmaceutical products, including recombinantly-produced vaccines and production cells, antibodies, and coagulation factors.
